Search results
Coexistence of psoriatic arthritis, atopic dermatitis may offer treatment insights
Medical Xpress· 2 days agoPsoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both...
It Took Me Years to Find the Right Psoriatic Arthritis Medication
Verywell Health via Yahoo News· 2 days agoAfter being diagnosed with psoriatic arthritis in 2016, it took LB Herbert years to find a psoriatic...
Brokerages Set Acelyrin, Inc. (NASDAQ:SLRN) Price Target at $23.67
ETF DAILY NEWS· 5 days agoShares of Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report) have earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com ...
Sketchy stem-cell treatments in Mexico led to drug-resistant infections
Live Science via Yahoo News· 3 days agoTwo similar cases involved men in their 60s — one from Arizona and one from Colorado. The Arizona...
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition...
WTRF Wheeling· 7 days agoCelltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale ...
Pharmaceutical giant Takeda is shutting down its San Diego office
U-T San Diego· 7 hours agoOpened in 2019, the local facility housed Takeda Ventures, a research and development site that...
Higher NSAID Dose Raises CVD Risk in Ankylosing Spondylitis
Medscape· 7 days agoNSAIDs, the primary pain management therapy for AS, increased the risk for vascular events and...
Stelara interactions: Other medications, alcohol, and more
Medical News Today· 6 days agoStelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions....
Stem cell treatments in Mexico linked to drug-resistant meningitis, joint infections
United Press International via Yahoo News· 7 days agoAntibiotic-resistant meningitis or severe, long-lasting joint infections: That's what three U.S....
AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts
ETF DAILY NEWS· 16 hours agoAbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued to clients and investors on Tuesday ...